ArticleCureus2026
Ketamine as a Novel Solution for Opioid-Refractory Pain in Radiation Necrosis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a 36-year-old female with recurrent metastatic melanoma, complicated by radiation necrosis of the left distal thigh musculature, who presented with intractable, debilitating pain approximately seven months following completion of local radiation therapy. Palliative Medicine was consulted for assistance with pain management. Prior to admission, the patient had failed to respond to escalating doses of oral oxycodone and transdermal fentanyl, given in conjunction with a multimodal regimen including acetaminophen, baclofen, celecoxib, duloxetine, and pregabalin. Just before presentation, the patient completed a prednisone taper for treatment of immune checkpoint inhibitor colitis, with suspicion that steroids were likely masking or partially treating pain before discontinuation. She was not a candidate for steroid re-initiation due to upcoming plans for tumor-infiltrating lymphocyte therapy. Despite escalating opioid dosing (up to oral morphine equivalent (OME) 598.75 mg), our patient continued to experience uncontrolled pain along with progressive sedation. We started her on ketamine 0.1 mg/kg/hr and titrated this over the next 24 hours to a final dose of 0.3 mg/kg/hr, which was then continued for 48 additional hours. Following completion of a three-day ketamine infusion, the patient's OME was reduced by 45% to 327.5 mg. In the months following hospital discharge, the patient was subsequently weaned off long-acting opioids and was able to return to her baseline functional status. No previous cases have been reported of the use of ketamine for the treatment of opioid-refractory pain secondary to radiation necrosis. In this case, we have demonstrated ketamine infusion as a successful treatment strategy for reducing our patient's opioid requirement, optimizing pain control, and helping to improve functional status and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.